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UPFRONT AROMATASE INHIBITORS (AI) IN EARLY BREAST
CANCER: AGAINST
F. Boccardo, P. Guglielmini, A. Rubagotti. Department of Medical
Oncology, University and National Cancer Research Institute, Genoa,
Italy
While several large trials have now established that AI are
more effective than tamoxifen (T) when used as adjuvant endo-
crine therapy, the optimal adjuvant strategy, in particular
whether AI should replace T from the beginning or after a few
years of T treatment, remains a matter of debate.
For some Authors, upfront use of an AI offers the best opportu-
nity to reduce the risk of early relapse, within the first 2–2.5 years
after surgery, for post-menopausal patients likely to harbour
tumours primarily resistant to T.1 There is some evidence that
HER2-overexpressing, low level of ER or PGR-negative tumours
might be less responsive to T and better suited to treatment with
AI at the onset.2 In the more recent analysis of the ATAC trial, at a
median follow-up time of 100 months, there was no significant
heterogeneity across the treatment subgroups, except for the
small subgroup of ER-positive and PgR-negative patients for
whom the benefit in favour of anastrozole appeared to be greater.3
However, this finding, has not been confirmed by the BIG 1–98 trial
data.4 Moreover, a retrospective analysis of the ATAC data per-
formed by Dowsett and coll. and focused on the relationship
between centrally tested, quantitative ER and PgR and HER-2 sta-
tus, with cancer recurrence, did not identify patients with differ-
ential relative benefit from anastrozole over T.5
In looking at the early relapse curves of the ATAC trial relative
to the women given Talone, one should also consider that, in this
cohort, about 70% of women were node-negative and did not
receive any adjuvant chemotherapy (CT), as they probably would
do nowadays, according to more recent guidelines.6,7 The most
recent results of the EBCTCG metanalysis and those of several
individual trials provide a clear evidence that the addition of CT
to T does significantly improve the RFS chance even in ER positive
tumours.8 Thus it is plausible to assume that the early advantage
of replacing Twith an AI, which should be theoretically related to
the increased chance of controlling primarily T resistant clones,
might be flawed in the patients candidate to receive adjuvant
CT as well. The most recent analysis of ATAC data relative to time
to recurrence according to assigned treatment appears to confirm
that in patients previously treatedwith CT the benefit achieved by
anastrozole was lower than the benefit achieved in the patients
treated with T alone and the difference anylonger statistically
significant.3
Another, may be more important, argument against the use of
upfront treatment with AI is the lack of any convincing effect of
such an approach on breast cancer and overall mortality,in spite
of the fact that both ATAC and BIG 1–98 trials are large and data
quite mature.3,9 No effect on mortality comes also from the met-
analysis of the two trials, which includes more than 9.000
patients.10 As cure still remains the major goal of adjuvant treat-
ment of breast cancer, it is questionable at this point wether
replacing Twith an AI since the beginning should really represent
the gold standard for all women with endocrine-sensitive
tumours, also in view of the side effects that so prolonged oestro-
gen-deprivation might exert on bone resorption or ischaemic dis-
ease and of the increased costs of treatment.11 In fact, in contrast
to previous findings, a small,but statistically significant, breast
cancer- and overall mortality advantage comes out from two of
the four trials on switching and from the different metanalysis
available so far,including the most recent AIOG metanalysis
which confirms the positive effect of switching on both breast-
cancer and overall mortality.10,12–15
In the absence of any direct comparative data between upfront
versus sequencing strategies, mathematical models, which are
basedonprevious trials data,weredeveloped to predict the relative
merits of the different strategies,and although conclusions are,
some-what ,contrasting all these models suggest that sequencing
should be expected to achieve comparable,if not better,results as
compared to the strategies based on the up-front use of AI.16
Treatment costs can represent another major issue which
might refrain from using AI. Data about drug costs, taken from
US published wholesale acquisition costs, showed that anastroz-
ole costs US$6.56 per day whereas generic T US $1.33. The
sequential regimen is promising in keeping treatment costs low,
because, intuitively, giving an AI for 2–3 years is cheaper that giv-
ing it for 5 years.17 Health economic studies confirmed that
switching is a cost-effective and a cost-useful option.
While awaiting the upcoming results from the sequential arms
of the BIG 1–98 trial and the data from the amended TEAM trial,
there is no doubt that switching to AI is not only strongly advisable
for patients already on treatmentwith T from2 or 3 years,butmight
represent a reasonable initial choice for all women with endocrine
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sensitive tumours,unless it might be reasonably argued that they
might be intolerant to or anyway unsuitable for receiving T.
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IS ORAL METRONOMIC CYCLOPHOSPHAMIDE (CTX) AN EFFEC-
TIVE PALLIATIVE TREATMENT FOR PATIENTS WITH META-
STATIC BREAST CARCINOMA (ABC)? EXPERIENCE FROM A
RETROSPECTIVE SERIES OF PATIENTS
H. Boussen a, G. Bellavia b, R. Agueli b, V. Gebbia b. aMedical
Oncology, Institut Salah Azaiz, Tunis, Tunisia. bUniversity of Palermo
La Maddalena Cancer Clinic, Palermo, Italy
Oral metronomic chemotherapy is a therapeutic option which
is particularly attractive for its ease of administrationand low toxic
burden. Its mechanism of action probably involves an anti-angio-
genetic effects rather a classical antiproliferative effect like stan-
dard maximally tolerated dose-based regimens. Patients and
methods: A retrospective analysis of 22 pts with ABC was carried
out with the aim of reporting activity in terms of response rate,
tumour-related symptoms control, outcome and toxicity. All
patients had hormonal therapy-resistant metastatic disease and
had previously received two lines of chemotherapy. All patients
were treated with oral CTX 50 mg/day without interruption until
re-evaluation or progressive disease. Results: An objective
response (1 complete and 2 partial responses) was seen in 14% of
patients (95%CL 5–28%). Stable disease with a median duration of
5 months (range 3–7months) was recorded in 8 cases (36%; 95%CL
16–56%) for a TGCR of 50%. Symptoms control was achieved in
54% of cases. Toxicity was very mild and easily manageable. No
cases of extra-haematological grade 3-toxicity were observed.
Grade 3 non-febrile neutropeniawere recorded in 9%of cases. Con-
clusions: Although retrospectively recorded data presented in this
study support the use of an oral metronomic chemotherapy in
patientswithABC. Relativelymild activity is however seen inheav-
ily pretreated patients without significant side-effects. Further
studies are warranted to optimise the treatment schedule and to
select patients who may benefit from such an approach.
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